Stocks & Investing
Stocks and Investing
Stocks and Investing
Mon, March 25, 2024
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Robyn Karnauskas Reiterated (BIIB) at Strong Buy and Held Target at $340 on, Mar 25th, 2024
Robyn Karnauskas of Truist Securities, Reiterated "Biogen Inc." (BIIB) at Strong Buy and Held Target at $340 on, Mar 25th, 2024.
Robyn has made no other calls on BIIB in the last 4 months.
There are 14 other peers that have a rating on BIIB. Out of the 14 peers that are also analyzing BIIB, 2 agree with Robyn's Rating of Hold. Following are those relevant analyst calls for the last 4 months
- Colin Bristow of "UBS" Maintained at Hold with Decreased Target to $250 on, Friday, February 16th, 2024
- Mohit Bansal of "Wells Fargo" Downgraded from Buy to Hold and Decreased Target to $240 on, Wednesday, February 14th, 2024
These are the ratings of the 12 analyists that currently disagree with Robyn
- Brian Abrahams of "RBC Capital" Reiterated at Buy and Held Target at $364 on, Tuesday, March 5th, 2024
- Salim Syed of "Mizuho" Maintained at Strong Buy with Decreased Target to $277 on, Thursday, February 22nd, 2024
- Sumant Kulkarni of "Canaccord Genuity" Maintained at Strong Buy with Decreased Target to $305 on, Tuesday, February 20th, 2024
- Eric Schmidt of "Cantor Fitzgerald" Reiterated at Buy and Held Target at $311 on, Tuesday, February 20th, 2024
- Evan Seigerman of "BMO Capital" Maintained at Buy with Decreased Target to $285 on, Wednesday, February 14th, 2024
- Jay Olson of "Oppenheimer" Maintained at Buy with Decreased Target to $290 on, Wednesday, February 14th, 2024
- Brian Skorney of "Baird" Maintained at Buy with Decreased Target to $316 on, Wednesday, February 14th, 2024
- Christopher Raymond of "Piper Sandler" Maintained at Buy with Decreased Target to $325 on, Wednesday, February 14th, 2024
- Ami Fadia of "Needham" Maintained at Strong Buy with Decreased Target to $300 on, Wednesday, February 14th, 2024
- Andrew Fein of "HC Wainwright & Co." Reiterated at Strong Buy and Held Target at $325 on, Wednesday, February 14th, 2024
- Paul Matteis of "Stifel" Maintained at Strong Buy with Decreased Target to $287 on, Thursday, December 14th, 2023
- Danielle Brill of "Raymond James" Upgraded from Hold to Buy and Held Target at $283 on, Thursday, December 7th, 2023
